Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-08-25

Clinical Trial Update: Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating efavirenz in HIV-1 infected adults with hepatic impairment to assess dosing considerations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EFAVIRENZ (efavirenz)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections, Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2010-08-25